Physician profile
Patrick Ray Vandehey
NPI 1568544880
$1,349.58
in general payments reported to CMS, 2019-2025
24 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $274 · 2022: $31.66 · 2024: $46.67 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142 · Debt Forgiveness: $46.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.27 |
| Debt Forgiveness | $46.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $230.98 | 2019-2020 | |
| Pfizer INC. | $202.23 | 2019-2025 | |
| Lilly USA, LLC | $88.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $82.46 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $64.74 | 2019-2020 | |
| Abbvie INC. | $63.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.25 | 2019-2020 | |
| Novo Nordisk INC | $53.93 | 2019-2020 | |
| Amgen INC. | $50.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.39 | 2019-2020 | |
| Baxter Healthcare | $46.67 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $45.09 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $42.83 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $33.08 | 2019-2020 | |
| Allergan, INC. | $27.29 | 2020 | |
| Grifols USA, LLC | $23.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.60 | 2019 | |
| Ibsa Pharma INC. | $14.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.11 | 2019 | |
| Tris Pharma INC | $11.65 | 2019 | |
| Assertio Therapeutics, INC. | $11.63 | 2019 | |
| Metuchen Pharmaceuticals | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Vandehey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.